UHB demonstrator interior noise control flight tests and analysis

The measurement and analysis of MD-UHB (McDonnell Douglas Ultra High Bypass) Demonstrator noise and vibration flight test data are described as they relate to passenger cabin noise. The analyses were done to investigate the interior noise characteristics of advanced turboprop aircraft with aft-mounted engines, and to study the effectiveness of selected noise control treatments in reducing passenger cabin noise. The UHB Demonstrator is an MD-80 test aircraft with the left JT8D engine replaced with a prototype UHB engine. For these tests, the UHB engine was a General Electric Unducted Fan, with either 8x8 or 10x8 counter-rotating propeller configurations. Interior noise level characteristics were studied for several altitudes and speeds, with emphasis on high altitude (35,000 ft), high speed (0.75 Mach) cruise conditions. The effectiveness of several noise control treatments was evaluated based on cabin noise measurements. The important airborne and structureborne transmission paths were identified for both tonal and broadband sources using the results of a sound intensity survey, exterior and interior noise and vibration data, and partial coherence analysis techniques. Estimates of the turbulent boundary layer pressure wavenumber-frequency spectrum were made, based on measured fuselage noise levels

Le Sanctuaire d’Apollon

Étienne Roland, Herbin Frédéric, Braun Jean-Pierre, Pavlopoulos Kosmas, Apostolopoulos G., Mathé Virginie, Chapoulie Rémy, Druez Marion. Le Sanctuaire d’Apollon. In: Bulletin de correspondance hellénique. Volume 133, livraison 2, 2009. pp. 609-623

Liver-injury Related To Amoxicillin-clavulanic Acid - Interlobular Bile-duct Lesions and Extrahepatic Manifestations

We report eight cases of liver injury related to amoxycillin-clavulanate, Liver biopsy performed in seven patients revealed varying degrees of injury to interlobular bile ducts in all cases. Lesions included irregularity of the nuclei, vacuolization of the cytoplasm, lymphocytic infiltration, destruction and endothelialization of the bile duct epithelium. Ductopenia was not observed. In two patients liver injury was accompanied by prominent extrahepatic manifestations (acute interstitial nephritis in one and acute lacrimal gland inflammation and sialadenitis with prolonged xerostomia in the other). We conclude that interlobular bile-duct lesions of varying severity are a common feature in liver injury related to amoxycillin-clavulanate, Side effects of the drug include acute interstitial nephritis and sialadenitis

Olmesartan-associated enteropathy: results of a national survey

BACKGROUND: Recently, a new enteropathy has been described: olmesartan-associated enteropathy. However, the association has been questioned: a phase 3 trial and a cohort study found no association between gastrointestinal events and olmesartan. AIM: To collect French cases of sartan-associated enteropathy to describe further this entity, confirm or refute causality, and determine if the association exists with other sartans. METHODS: French gastroenterologists were invited to report cases of sartan-associated enteropathy and collect clinical, biological and histological data. Patients with diarrhoea and histological duodenal abnormalities were included. RESULTS: Thirty-six patients with olmesartan-associated enteropathy were reported, including 32 with villous atrophy and four without. There was only one patient with irbesartan-associated enteropathy. None of the patients died. Patients with villous atrophy had diarrhoea, vomiting, renal failure, hypokalaemia, body weight loss and hypoalbuminaemia. Thirty-one patients were hospitalised; four required intensive care. Anti-transglutaminase and anti-enterocyte antibodies were negative; anti-nuclear antibodies were positive (9/11). Endoscopic duodenal biopsies showed villous atrophy (32/32) and polyclonal intra-epithelial CD3+CD8+ lymphocytosis (11/11). Exactly, 14/15 patients responded to steroids and/or immunosuppressants, prescribed because of suspected autoimmune enteropathy. Ten olmesartan interruptions were followed by reintroductions before steroids or immunosuppressants. Interruptions were followed by remissions (9/10), but reintroductions were followed by relapses (9/9). Twenty-nine patients were in remission since olmesartan interruption, including 26 without immunosuppressants. Patients with normal villi had similar clinical characteristics, but mild histological abnormalities (intra-epithelial lymphocytosis and lamina propria lymphocytic infiltration). CONCLUSIONS: Olmesartan causes a severe and immune-mediated enteropathy, with or without villous atrophy. Enteropathy associated with other sartans seems to be very rare